GlobeNewswire Inc.··Sanofi And RegeneronSanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria
FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval